2 Nov 2018 12:36
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
2 November 2018
Sinclair Pharma plc
("Sinclair" or the "Company")
Rule 2.9 Announcement
Â
In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, as at 08:00 am on 2 November 2018, it had 517,657,084 ordinary shares of 1 pence each in issue and admitted to trading on AIM. No ordinary shares are held in treasury. Accordingly, the total number of voting rights in Sinclair is 517,657,084. The International Securities Identification Number ("ISIN") for Sinclair's ordinary shares is GB0033856740.
Â
For further information, please contact:
Sinclair Pharma plc | +44 (0) 20 7467 6920 |
Chris Spooner | |
Alan Olby | |
Andy Crane | |
Rothschild (Lead Financial Adviser to Sinclair) | +44 (0) 20 7280 5000 |
Dominic Hollamby | |
Julian Hudson Josh Johnson | |
  Peel Hunt LLP (Joint Financial Adviser, NOMAD and Joint Broker to Sinclair) |   +44 (0)20 7418 8900 |
James Steel | |
Michael Nicholson | |
Oliver Jackson | |
FTI Consulting (Public Relations Adviser to Sinclair) | + 44 (0) 203 727 1000 |
Ben Atwell | |
Brett Pollard | |
Stephanie Cuthbert |
Â